US 11,918,728 B2
Therapeutic compositions for viral-associated disease states and methods of making and using same
Carol A. Rae, Rapid City, SD (US); Jan Simoni, Rapid City, SD (US); Grace Simoni, Rapid City, SD (US); John F. Moeller, Rapid City, SD (US); and Jose A. Diaz-Aunon, Rapid City, SD (US)
Assigned to Immutrix Therapeutics, Inc., Rapid City, SD (US)
Filed by ImMutriX Therapeutics, Inc., Rapid City, SD (US)
Filed on Nov. 6, 2020, as Appl. No. 17/091,214.
Application 17/091,214 is a continuation in part of application No. 17/008,783, filed on Sep. 1, 2020, granted, now 11,759,561.
Application 17/008,783 is a continuation of application No. 15/584,796, filed on May 2, 2017, granted, now 10,773,011, issued on Sep. 15, 2020.
Application 15/584,796 is a continuation of application No. 14/642,538, filed on Mar. 9, 2015, granted, now 9,669,151, issued on Jun. 6, 2017.
Claims priority of provisional application 62/055,392, filed on Sep. 25, 2014.
Claims priority of provisional application 61/981,061, filed on Apr. 17, 2014.
Prior Publication US 2021/0052803 A1, Feb. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 1/36 (2006.01); B01J 20/20 (2006.01); B01J 47/02 (2017.01); A61M 5/165 (2006.01)
CPC A61M 1/3679 (2013.01) [B01J 20/20 (2013.01); B01J 47/02 (2013.01); A61M 5/165 (2013.01); A61M 2202/0021 (2013.01); A61M 2202/0042 (2013.01); A61M 2202/0413 (2013.01); A61M 2202/206 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of treating a subject infected with SARS-CoV-2 comprising:
obtaining a bodily fluid from the subject having a level of COVID-19 disease mediators (y);
contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate;
contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the weight ratio of SCP to anion exchange resin is from about 1:100 to produce a second filtrate;
contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the weight ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and
administering the third filtrate to the subject.